Edesa Biotech (EDSA) Stock Price, News & Analysis

Company Overview

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Key Stats

• Today's Range: $2.49 to $2.60
• 50-Day Range: $1.71 to $3.25
• 52-Week Range: $1.55 to $5.59
• Volume: 36,882 shs
• Average Volume: 489,469 shs
• Market Capitalization: $17.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Edesa Biotech Stock Analysis - MarketRank™

Edesa Biotech scored higher than 71% of companies evaluated by MarketBeat, and ranked 272nd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Edesa Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Edesa Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Edesa Biotech are expected to grow in the coming year, from ($1.75) to ($1.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Edesa Biotech is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Edesa Biotech is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Edesa Biotech has a P/B Ratio of 14.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.77% of the float of Edesa Biotech has been sold short.

Short Interest Ratio / Days to Cover

Edesa Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edesa Biotech has recently decreased by 87.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Edesa Biotech does not currently pay a dividend.

Dividend Growth

Edesa Biotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.77% of the float of Edesa Biotech has been sold short.

Short Interest Ratio / Days to Cover

Edesa Biotech has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Edesa Biotech has recently decreased by 87.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: N/A

News Sentiment

Edesa Biotech has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Edesa Biotech this week, compared to 0 articles on an average week.

Search Interest

3 people have searched for EDSA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Edesa Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Edesa Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.00% of the stock of Edesa Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.50% of the stock of Edesa Biotech is held by institutions.

EDSA Stock Analysis - Frequently Asked Questions

How have EDSA shares performed this year?

Edesa Biotech's stock was trading at $1.68 at the start of the year. Since then, EDSA shares have increased by 50.3% and is now trading at $2.5250.
View the best growth stocks for 2025 here.

How were Edesa Biotech's earnings last quarter?

Edesa Biotech, Inc. (NASDAQ:EDSA) issued its quarterly earnings data on Friday, February, 14th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.17.

When did Edesa Biotech's stock split?

Edesa Biotech shares reverse split before market open on Wednesday, October 11th 2023. The 1-7 reverse split was announced on Tuesday, October 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Who are Edesa Biotech's major shareholders?

Edesa Biotech's top institutional investors include Citadel Advisors LLC (1.18%) and Two Sigma Securities LLC (0.44%). Insiders that own company stock include Pardeep Nijhawan, Der Velden Peter Van and Michael J Brooks.
View institutional ownership trends.

How do I buy shares of Edesa Biotech?

Shares of EDSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Edesa Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Edesa Biotech investors own include Pfizer (PFE), Ford Motor (F), Moderna (MRNA), Occidental Petroleum (OXY), Plug Power (PLUG), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 2/14/2025
• Today: 3/26/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EDSA
• CIK: 1540159
• Web: www.edesabiotech.com
• Phone: (289) 800-9600
• Fax: 805-488-2889
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.00
• High Stock Price Target: $21.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +731.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,170,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -233.69%
• Return on Assets: -124.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.09
• Quick Ratio: 0.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 14.03

Miscellaneous

• Outstanding Shares: 6,993,000
• Free Float: 2,601,000
• Market Cap: $17.66 million
• Optionable: Not Optionable
• Beta: 0.77